Clinical trial NCT04272788: Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
Official title: Association of Breg and Treg With the Clinical Effects of Infliximab in the Treatment of Patients With Crohn's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Crohn Disease
Keywords: Crohn Disease
Infliximab
Treg
Breg
Lead sponsor: Second Affiliated Hospital of Wenzhou Medical University
Sponsor class: OTHER
First posted: 2020-02-17
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from the gastroenterology department at the Second Affiliated Hospital of Wenzhou Medical University are eligible for entry.

Healthy controls are recruited at Health Examination Center of the Second Affiliated Hospital of Wenzhou Medical University.

Brief summary: Aims: The main aim of this study is to access the predictive value of Treg and Breg for the clinical effect of Infliximab in the treatment through analyzing the relationship between Breg and Treg and the efficacy of Infliximab.

Design: It is a prospective, observational study. In the treatment group, 32 patients with Crohn's disease (CD) about to start Infliximab-treatment are recruited. They have blood samples drawn at week 0 and 14 of Infliximab treatment. 33 healthy individuals serve as a control group. Controls are only investigated once. All treatment and follow-up are according to national guidelines. The frequencies of Treg and Breg are investigated using flow cytometry. Subjects data are extracted from various registries.

Detailed description: 1. Patients with CD at initial active stage are collected from department of gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. The diagnosis of CD is based on clinical, endoscopic, laboratory, radiologic, histo-pathological findings and close follow-up in accordance with the guidelines for the diagnosis and treatment of CD issued by the European Crohn's Disease and Colitis in 2016. Healthy individuals are collected from the Health Examination Center of the Second Affiliated Hospital of Wenzhou Medical University as the healthy controls. The demographic and characteristic information of CD patients and healthy controls are recorded.
2. Infliximab (5mg/kg) is given intravenously at week 0, 2 and 6 to induce CD remission, and then maintained with the same dose of Infliximab every 8 weeks.
3. CD patients are followed for 14 weeks after the first administration of infliximab. At week 14 of Infliximab treatment, according to symptoms, CDAI and endoscopic mucosal healing, CD patients are classified as remission group (CDAI\<150 and endoscopic mucosal healing, R group) and non-remission group (CDAI≥150 and/or mucosal non-healing group, N group).
4. C-reactive protein (CRP), leucocyte count (WBC), platelet count (PLT), erythrocyte sedimentation rate (ESR) are detected in CD patients to assess the clinical efficacy at week 0 and 14 of Infliximab treatment respectively.
5. Approximate 5 mL of peripheral fasting venous blood is obtained from every CD patient (at weeks 0 and 14 of Infliximab treatment) and healthy controls. Peripheral blood mononuclear cells (PBMCs) are isolated from the blood samples.
6. Multi-color flow cytometry is applied to examine the frequency of Breg (CD3-CD19+IL-10+ B cell) in B cell: PBMCs are resuspended in RPMI 1640 medium, supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin Solution, added in a 96-well flat-bottom culture plate. Then the obtained cells are stimulated with lipopolysaccharide for 48 hours, cultured at 37℃ in 5% CO2 in the incubator, and added Phorbol 12-myristate 13-acetate and ionomycin and Brefeldin A during the final 5 hours. After stimulated and cultured in vitro, PBMCs are stained with FITC-conjugated anti-human CD3 antibodies, APC-conjugated anti-human CD19 antibodies for 30 minutes with blocking light at 4℃. Then stained cells are fixed and permeabilized using a Cytofix/Cytoperm kit and stained with PE-conjugated anti-human IL-10 antibodies for 2 hours at 4℃ that protected form light. Flow staining buffer solution resuspends cells before flow cytometry detection of Breg.
7. Multi-color flow cytometry is applied to examine the frequency of Treg (CD4+CD25+Foxp3+ T cell) in CD4+ T cell: PBMCs are stained with FITC-conjugated anti-human CD4 antibodies, APC-conjugated anti-human CD25 antibodies for 30 minutes with blocking light at 4℃. Stained cells are added fixing buffer and incubated at 4℃ in the dark overnight, then stained with PE-conjugated anti-human FoxP3 antibodies for 2 hours at 4℃ that protected form light. Flow staining buffer solution resuspends cells before flow cytometry detection of Treg.

Eligibility criteria: CD patients

Inclusion Criteria:

1. Crohn's Disease at initial active stage with CDAI ≥150.
2. Starting Infliximab treatment

Exclusion Criteria:

1. Significant co-morbidity (e.g. cancer, intestinal tuberculosis, ischemic enteritis, radiation enteritis)
2. Other immunological disease (e.g. diabetes, rheumatoid arthritis systemic lupus erythematosus)
3. Current treatment with glucocorticoids, immunosuppressants and biological agents

Healthy controls

Inclusion Criteria:

1. No current disease
2. No daily drug use

Exclusion Criteria:

1. Significant co-morbidity (e.g. cancer, intestinal tuberculosis, ischemic enteritis, radiation enteritis)
2. Other immunological disease (e.g. diabetes, rheumatoid arthritis systemic lupus erythematosus)
3. Current treatment with glucocorticoids, immunosuppressants and biological agents

Primary outcomes:
measure: Change of the frequency of Treg in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of the frequency of Breg in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of the frequency of Treg in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of the frequency of Breg in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
Secondary outcomes:
measure: Change of Crohn's disease activity index (CDAI) in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of C-reactive protein (CRP) in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of leucocyte count (WBC) in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of platelet count (PLT) in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of erythrocyte sedimentation rate (ESR) in R group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of Crohn's disease activity index (CDAI) in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of C-reactive protein (CRP) in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of leucocyte count (WBC) in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of platelet count (PLT) in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
measure: Change of erythrocyte sedimentation rate (ESR) in N group
timeFrame: week 0 of Infliximab treatment, week 14 of Infliximab treatment
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: SAHWenzhouMU
state: Zhejiang
Study officials:
affiliation: Second Affiliated Hospital of Wenzhou Medical University
name: Yi Jiang, PhD
role: PRINCIPAL_INVESTIGATOR
References: